Janux Therapeutics, Inc. (JANX)

Over the past six months, Janux Therapeutics' stock has been influenced by several key events. Positive interim clinical data for JANX007 and a collaboration agreement with Bristol Myers Squibb positively impacted investor sentiment. Financial results for Q4 2025 and Q1 2026 showed collaboration revenue and a strong cash position, while the nomination of a development candidate under the Bristol Myers Squibb collaboration triggered a milestone payment. The first patient was dosed in a Phase 1 study of JANX014, marking pipeline progress. The discontinuation of clinical development for JANX008 was announced, reflecting resource prioritization.

As a clinical-stage biopharmaceutical company, Janux Therapeutics does not experience traditional demand seasonality. The demand for its product candidates is driven by clinical trial progress, regulatory approvals, and market adoption, rather than seasonal fluctuations. The company's revenue is currently derived from collaboration agreements and milestone payments.

Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing next-generation immunotherapies for cancer and autoimmune diseases. Founded in 2017 and based in San Diego, California, Janux utilizes proprietary technology platforms to create novel drug candidates that generate potent immune responses while minimizing safety concerns. The company's pipeline includes Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms, with product candidates like JANX007, JANX014, JANX013 and JANX011 in various stages of clinical development. Janux has strategic collaborations with Merck & Co. and Bristol-Myers Squibb.

Janux Therapeutics is headquartered in San Diego, California, and its operations primarily involve research, development, and clinical trials. While partnerships with global pharmaceutical companies suggest a broader future reach, its current operational footprint is centered in San Diego.

Janux Therapeutics maintains a positive brand reputation in the biotechnology and immuno-oncology space due to its innovative technology platforms and strategic partnerships. Positive clinical data for JANX007, collaborations with Merck and Bristol Myers Squibb, and the advancement of its pipeline have positively affected its reputation. The discontinuation of JANX008 was framed as a strategic decision, reflecting positively on management.

Janux Therapeutics has a diverse ownership structure, including significant institutional and insider holdings. As of May 5, 2026, there were 191 institutional owners holding a total of 61,607,148 shares, with major holders including Ra Capital Management, Janus Henderson Group Plc, and BlackRock, Inc. Insiders own approximately 19.71% of the company's stock, with Avalon Ventures XI LP being the largest individual shareholder.